|
1) Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002; 20: 197-216
|
|
|
|
2) Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006; 7: 774-8
|
|
|
|
|
|
3) Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol. 2007; 3: 382-90
|
|
|
|
|
|
4) Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418: 191-5
|
|
|
|
|
|
5) Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5: 331-42
|
|
|
|
|
|
6) Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007; 8: 487-96
|
|
|
|
|
|
7) Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000; 405: 354-60
|
|
|
|
|
|
8) Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004; 5: 825-30
|
|
|
|
|
|
9) Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol. 2005; 26: 231-46
|
|
|
|
|
|
10) Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004; 164: 441-9
|
|
|
|
|
|
11) Limana F, Germani A, Zacheo A, et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit＋ cell proliferation and differentiation. Circ Res. 2005; 97: e73-83
|
|
|
|
|
|
12) Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285: 248-51
|
|
|
|
|
|
13) Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004; 101: 296-301
|
|
|
|
|
|
14) Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med. 2004; 10: 1216-21
|
|
|
|
|
|
15) Abeyama K, Stern DM, Ito Y, et al. The N- terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005; 115: 1267-74
|
|
|
|
|
|
16) Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005; 94: 975-9
|
|
|
|
|
|
17) Ito T, Kawahara K, Nakamura T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007; 5: 109-16
|
|
|
|
|
|
18) Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005; 202: 271-81
|
|
|
|
|
|
19) Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006; 203: 513-8
|
|
|
|
|
|
20) Colman RW. Are hemostasis and thrombosis two sides of the same coin？ J Exp Med. 2006; 203: 493-5
|
|
|
|
|
|
21) Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007; 104: 6388-93
|
|
|
|
|
|
22) Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med. 2005; 11: 475-7
|
|
|
|
|
|
23) Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007; 5: 31-41
|
|
|
|
|